| Assessment Status | Rapid Review Complete |
| HTA ID | 26041 |
| Drug | Depemokimab |
| Brand | Exdensur® |
| Indication | Depemokimab (Exdensur®) is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterized by blood eosinophil count in adults and adolescents aged 12 years and older who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another asthma controller. |
| Assessment Process | |
| Rapid review commissioned | 21/08/2026 |
| Rapid review completed | 22/09/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that depemokimab not be considered for reimbursement for this indication at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here